Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Inpatient, Phase 2, Double-blind, Placebo-Controlled Dose Ranging Study of LY2140023 in Patients With DSM-IV Schizophrenia
Brief Summary: The purpose of this study is to test the hypothesis that 1 or more dose levels of LY2140023 given orally to patients with schizophrenia twice daily for 4 weeks will have significantly greater effect than placebo.


Options:
A: Arm Label: 160 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 4 mg Risperidone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 80 mg LY2140023; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): 4 mg Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 160 mg LY2140023, 80 mg LY2140023
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cariprazine 1.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 3.0 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 4.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Risperidone 4.0 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Risperidone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 1.5 mg, Cariprazine 3.0 mg, Cariprazine 4.5 mg | Intervention Type: DRUG; Name: Risperidone; Assigned to Arm(s): Risperidone 4.0 mg
C: Arm Label: 80 milligrams (mg) LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 40 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 10 mg LY2140023, BID; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 10 mg LY2140023, BID, 40 mg LY2140023, BID, 80 milligrams (mg) LY2140023, BID | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: LY2140023 | Arm Label: 5; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 6; Type: ACTIVE_COMPARATOR; Interventions: Drug: Olanzapine, Drug: Placebo | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: LY2140023; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Olanzapine; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 5

Answer: D